New opportunities in sight as first sales approach
Immunovia | 02/10/2017

Immunovia is on track to start commercialising its PanCan-d test for the early detection of pancreatic cancer in high-risk patients in 2018. To this end,…

Final top-line IMMray data in Lupus, FY16 results
Immunovia | 30/03/2017

Immunovia has announced final top-line data of the IMMray platform from a retrospective study in autoimmune diseases. The study showed that the IMMray…

First NCI collaboration in the diabetes opportunity
Immunovia | 20/12/2016

Immunovia has taken key steps in both opportunities being pursued for its IMMray PanCan-d test for the early detection of pancreatic cancer. In diabetes,…